Literature DB >> 27138184

Community Screening for Nonischemic Cardiomyopathy in Asymptomatic Subjects ≥65 Years With Stage B Heart Failure.

Hong Yang1, Ying Wang1, Mark Nolan1, Kazuaki Negishi2, Peter M Okin3, Thomas H Marwick4.   

Abstract

A process to identify and target a selected population at risk of heart failure (HF) could facilitate screening and prevention. We sought to develop an effective screening process from clinical characteristics, functional capacity, and electrocardiogram (ECG). Asymptomatic subjects ≥65 years, with ≥1 HF risks were recruited from the community. Subjects with valvular disease, ejection fraction <40%, and atrial fibrillation were excluded. All underwent clinical evaluation including assessment of HF risk using Framingham HF score and Atherosclerosis Risk in Communities (ARIC) score, ECG, echocardiography, and 6-minute walk (6 MW) test. After 14 ± 4 months, new HF was assessed using Framingham criteria. A randomly selected derivation cohort was used to integrate ARIC score and 6 MW in a classification and regression tree (CART) analysis, with the remaining population used for validation. Of the 419 subjects (age 70 ± 5; 48% men), 52 developed HF. ARIC was more effective than the Framingham HF score (area under the curve 0.65 vs 0.53, p = 0.01). CART selected ARIC (>9.5%) and 6 MW (<501 m) as cutoffs to define low-, intermediate-, and high-risk groups. Abnormal ECG further divided the intermediate group into high and low risks. The 134 subjects identified as high risk by a combined clinical and electrocardiographic strategy showed more echocardiographic features of cardiac dysfunction including LV mass, mitral e', mitral E/e', and longitudinal strain (p <0.01). New HF was significantly more frequent than in the remaining patients (20% vs 10%, p = 0.003; hazard ratio 2.08, 95% confidence interval 1.21 to 3.57, p = 0.008). Thus, initial clinical risk and electrocardiographic assessment facilitate effective HF screening by identifying a high-risk group.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27138184     DOI: 10.1016/j.amjcard.2016.03.045

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

Review 1.  The American Heart Association Heart Failure Summit, Bethesda, April 12, 2017.

Authors:  Pamela N Peterson; Larry A Allen; Paul A Heidenreich; Nancy M Albert; Ileana L Piña
Journal:  Circ Heart Fail       Date:  2018-10       Impact factor: 8.790

Review 2.  The roles of global longitudinal strain imaging in contemporary clinical cardiology.

Authors:  Toshimitsu Kato; Tomonari Harada; Kazuki Kagami; Masaru Obokata
Journal:  J Med Ultrason (2001)       Date:  2022-01-28       Impact factor: 1.314

3.  Clinical Skin Aging Score and Risk of Degenerative Cardiovascular Diseases.

Authors:  Soheir Ghonemy; Mohamed Mohamed Mahmoud Nasr; Mohammad Soliman; Heba Allah Hosiney
Journal:  J Clin Aesthet Dermatol       Date:  2021-02-01

4.  Refocusing on the Primary Prevention of Heart Failure.

Authors:  Lua A Jafari; Rachel M Suen; Sadiya S Khan
Journal:  Curr Treat Options Cardiovasc Med       Date:  2020-05-29

5.  Association of depression with evolution of heart failure in patients with type 2 diabetes mellitus.

Authors:  Ying Wang; Hong Yang; Mark Nolan; John Burgess; Kazuaki Negishi; Thomas H Marwick
Journal:  Cardiovasc Diabetol       Date:  2018-01-24       Impact factor: 9.951

6.  Incidence of Preclinical Heart Failure in a Community Population.

Authors:  Kathleen A Young; Christopher G Scott; Richard J Rodeheffer; Horng H Chen
Journal:  J Am Heart Assoc       Date:  2022-07-20       Impact factor: 6.106

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.